


# PATENT COOPERATION TREATY

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Article 36 and Rule 70)

Applicant's or agent's file reference SCB828PCT		<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/PEA/416)
International application No. PCT/EP 03/14719	International filing date (day/month/year) 22.12.2003	Priority date (day/month/year) 23.12.2002
International Patent Classification (IPC) or both national classification and IPC C12Q1/68		
Applicant ISTITUTO NAZIONALE PER LO STUDIO E LA CURA.. et al		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 5 sheets, including this cover sheet.</p> <p><input checked="" type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of 1 sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the opinion</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>		
Date of submission of the demand  12.07.2004		Date of completion of this report  01.02.2005
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		Authorized Officer  Knudsen, H  Telephone No. +49 89 2399-8696



# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP 03/14719

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17):*

### Description, Pages

1-13 as originally filed

### Claims, Numbers

6 (part), 7-11 as originally filed

1-5, 6 (part) filed with telefax on 20.01.2005

### Drawings, Sheets

1/3-3/3 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. **PCT/EP 03/14719**

---

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)).

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

1. Statement

Novelty (N)	Yes: Claims	1-11
	No: Claims	
Inventive step (IS)	Yes: Claims	1-11
	No: Claims	
Industrial applicability (IA)	Yes: Claims	1-11
	No: Claims	

2. Citations and explanations

**see separate sheet**

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP 03/14719

**Re Item V**

**Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

Reference is made to the following document/s/:

- D1: EP-A-1 158 055 (ANKER PHILIPPE ; STROUN MAURICE (CH); CHEN XU QI (US)) 28 November 2001 (2001-11-28)
- D2: WO 99/41406 A (UNIV MARYLAND) 19 August 1999 (1999-08-19)
- D3: KOK DE J B ET AL: "Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues" CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY. WINSTON, US, vol. 46, no. 3, March 2000 (2000-03), pages 313-318, XP002176598 ISSN: 0009-9147

**NOVELTY:**

D1 discloses an assay for determining the amount of RNA encoding hTERT enzyme in plasma or serum (see claim 1 and [0017]. The assay may be carried out as RT-PCR [0016] and the result analysed by electrophoresis [0020].

D2 discloses assays for determining the amount of RNA encoding hTERT enzyme or hTERT enzyme activity in plasma or serum (see claim 1, page 12 and p.13, last paragraph and Example 2. The assay may be carried out as RT-PCR and the result analysed by electrophoresis.

Thus, the method of claim 1 differs from both D1 and D2 in that it determines total circulating DNA in a plasma sample instead of RNA and employs a molecular beacon labelled with fluorophore and quencher and measures the fluorescence for the detection of the amplified DNA. Claims 1-11 are therefore considered novel.

**INVENTIVE STEP:**

In view of the results shown in the application and the scientific article "Journal of Clinical Oncology, vol. 21(21), p.3891-3893, (2003), it appears that the method of claim 1 has a sensitivity and specificity higher than the prior art methods for determining cancer via plasma DNA.

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/EP 03/14719

The prior art documents, D1 and D2, explain that DNA encoding certain proteins when found in blood samples are known markers of tumours and that the overexpression of hTERT (see D3) differs from the DNA markers in that it is a marker of all tumour types. However, none of the prior art documents suggest that the determination of genomic DNA of hTERT in blood samples represents a better tumour marker than the tumour markers of the prior art. Thus, the claimed solution to the problem of providing a better tumour marker would not be obvious to the skilled person and claims 1-11 therefore are considered inventive.

**INDUSTRIAL APPLICABILITY:**

Present claims 1-11 are considered industrially applicable.

**FURTHER REMARKS:**

It seems that the use of primers capable of amplifying both hTERT mRNA and DNA is not excluded from the claims. However, such primers would not be useful in determining the concentration of circulating total DNA, since the presence of RNA in the DNA preparation cannot be excluded. Claims 1-4 and 7-11 therefore lack clarity.